Patents by Inventor Brian H. Heasley

Brian H. Heasley has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240317728
    Abstract: The present embodiments are directed, in part, to processes and compositions that can, for example, be used in the preparation compounds of Formula (I), or a pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: October 26, 2023
    Publication date: September 26, 2024
    Inventors: Brian H. Heasley, Jennifer Wilent, Patrick J. Koestler
  • Patent number: 11884655
    Abstract: The present embodiments are directed, in part, to processes and compositions that can, for example, be used in the preparation compounds of Formula (I), or a pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: November 17, 2020
    Date of Patent: January 30, 2024
    Assignee: Trevena, Inc.
    Inventors: Brian H. Heasley, Jennifer Wilent, Patrick J. Koestler
  • Publication number: 20210147402
    Abstract: The present embodiments are directed, in part, to processes and compositions that can, for example, be used in the preparation compounds of Formula (I), or a pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: November 17, 2020
    Publication date: May 20, 2021
    Inventors: Brian H. Heasley, Jennifer Wilent, Patrick J. Koestler
  • Patent number: 10807992
    Abstract: The present invention relates to single enantiomer isothiazoline compounds of formula (I): and methods of synthesizing the compounds. The compounds are useful for combating or controlling invertebrate pests, in particular arthropod pests and nematodes. The invention also relates to a method for controlling invertebrate pests by using these compounds and to veterinary compositions comprising said compounds.
    Type: Grant
    Filed: November 15, 2018
    Date of Patent: October 20, 2020
    Assignee: Avista Pharma Solutions, Inc.
    Inventors: Jason D. Speake, Bakela Nare, Joe B. Perales, Keqiang Li, Cisco Bee, Jeffrey A. Adams, Kurt S. Van Horn, Brian H. Heasley
  • Publication number: 20190152983
    Abstract: The present invention relates to single enantiomer isothiazoline compounds of formula (I) and methods of synthesizing the compounds. The compounds are useful for combating or controlling invertebrate pests, in particular arthropod pests and nematodes. The invention also relates to a method for controlling invertebrate pests by using these compounds and to veterinary compositions comprising said compounds.
    Type: Application
    Filed: November 15, 2018
    Publication date: May 23, 2019
    Inventors: Jason D. Speake, Bakela Nare, Joe B. Perales, Keqiang Li, Cisco Bee, Jeffrey A. Adams, Kurt S. Van Horn, Brian H. Heasley
  • Patent number: 10183935
    Abstract: Novel benzamide derivatives of formula (I) wherein W1, W2, R1 to R10 and X have the meaning according to the claims, are positive allosteric modulators of the FSH receptor, and can be employed, inter alia, for the treatment of fertility disorders.
    Type: Grant
    Filed: April 26, 2017
    Date of Patent: January 22, 2019
    Assignee: Merck Patent GmbH
    Inventors: Henry Yu, Thomas E. Richardson, Pandi Bharathi, Brian H. Heasley, Matthew G. Jenks, Robert J. Foglesong
  • Patent number: 9938262
    Abstract: Novel benzamide derivatives of formula (I) wherein W1, W2, R1 to R7, R6, X and Y have the meaning according to the claims, are positive allosteric modulators of the FSH receptor, and can be employed, inter alia, for the treatment of fertility disorders.
    Type: Grant
    Filed: October 3, 2016
    Date of Patent: April 10, 2018
    Assignee: Merck Patent GmbH
    Inventors: Henry Yu, Andreas Goutopoulos, Thomas E. Richardson, Jiezhen Li, Brian H. Heasley, Pandi Bharathi
  • Patent number: 9498475
    Abstract: Novel benzamide derivatives of formula (I) wherein W1, W2, R1 to R7, R6, X and Y have the meaning according to the claims, are positive allosteric modulators of the FSH receptor, and can be employed, inter alia, for the treatment of fertility disorders.
    Type: Grant
    Filed: September 24, 2015
    Date of Patent: November 22, 2016
    Assignee: Merck Patent GmbH
    Inventors: Henry Yu, Andreas Goutopoulos, Thomas E. Richardson, Jiezhen Li, Brian H. Heasley, Pandi Bharathi
  • Patent number: 9409897
    Abstract: Novel benzamide derivatives of formula (I) wherein W1, W2, R1 to R10 and X have the meaning according to the claims, are positive allosteric modulators of the FSH receptor, and can be employed, inter alia, for the treatment of fertility disorders.
    Type: Grant
    Filed: January 9, 2013
    Date of Patent: August 9, 2016
    Assignee: Merck Patent GmbH
    Inventors: Henry Yu, Thomas E. Richardson, Pandi Bharathi, Brian H. Heasley, Matthew G. Jenks, Robert J. Foglesong
  • Patent number: 9181226
    Abstract: Novel benzamide derivatives of formula (I) wherein W1, W2, R1 to R7, R8, X and Y have the meaning according to the claims, are positive allosteric modulators of the FSH receptor, and can be employed, inter alia, for the treatment of fertility disorders.
    Type: Grant
    Filed: July 17, 2012
    Date of Patent: November 10, 2015
    Assignee: Merck Patent GmbH
    Inventors: Henry Yu, Jiezhen Li, Thomas E. Richardson, Pandi Bharathi, Brian H. Heasley, Andreas Goutopoulos
  • Patent number: 9040560
    Abstract: The invention provides novel substituted amino azaheterocyclic carboxamide compounds according to Formula (I), their manufacture and use for the treatment of hyperproliferative diseases, such as cancer.
    Type: Grant
    Filed: December 13, 2013
    Date of Patent: May 26, 2015
    Assignee: Merck Patent GmbH
    Inventors: Amanda E. Sutton, Thomas E. Richardson, Bayard R. Huck, Srinivasa R. Karra, Xiaoling Chen, Yufang Xiao, Andreas Goutopoulos, Ruoxi Lan, David Perrey, Harold George Vandeveer, Lesley Liu-Bujalski, Frank Stieber, Brian L. Hodous, Hui Qiu, Reinaldo C. Jones, Brian H. Heasley
  • Publication number: 20150011562
    Abstract: Novel benzamide derivatives of formula (I) wherein W1, W2, R1 to R10 and X have the meaning according to the claims, are positive allosteric modulators of the FSH receptor, and can be employed, inter alia, for the treatment of fertility disorders.
    Type: Application
    Filed: January 9, 2013
    Publication date: January 8, 2015
    Inventors: Henry Yu, Thomas E. Richardson, Pandi Bharathi, Brian H. Heasley, Matthew G. Jenks, Robert J. Foglesong
  • Publication number: 20140107156
    Abstract: The invention provides novel substituted amino azaheterocyclic carboxamide compounds according to Formula (I), their manufacture and use for the treatment of hyperproliferative diseases, such as cancer.
    Type: Application
    Filed: December 13, 2013
    Publication date: April 17, 2014
    Applicant: Merck Patent GmbH
    Inventors: Amanda E. Sutton, Thomas E. Richardson, Bayard R. Huck, Srinivasa R. Karra, Xiaoling Chen, Yufang Xiao, Andreas Goutopoulos, Ruoxi Lan, David Perrey, Harold George Vandeveer, Lesley Liu-Bujalski, Frank Steiber, Hui Qiu, Reinaldo C. Jones, Brian H. Heasley
  • Patent number: 8637532
    Abstract: The invention provides novel substituted amino azaheterocyclic carboxamide compounds according to Formula (I), their manufacture and use for the treatment of hyperproliferative diseases, such as cancer.
    Type: Grant
    Filed: February 4, 2010
    Date of Patent: January 28, 2014
    Assignee: Merck Patent GmbH
    Inventors: Amanda E. Sutton, Ruoxi Lan, Thomas E. Richardson, David Perrey, Harold George Vandeveer, Bayard R. Huck, Srinivasa R. Karra, Xiaoling Chen, Yufang Xiao, Lesley Liu-Bujalski, Andreas Goutopoulos, Frank Stieber, Brian L. Hodous, Hui Qiu, Reinaldo Jones, Brian H. Heasley
  • Patent number: 8188085
    Abstract: Novel derivatives of enfumafungin are disclosed herein, along with their pharmaceutically acceptable salts, hydrates and prodrugs. Also disclosed are compositions comprising such compounds, methods of preparing such compounds and methods of using such compounds as antifungal agents and/or inhibitors of (1,3)-?-D-glucan synthase. The disclosed compounds, their pharmaceutically acceptable salts, hydrates and prodrugs, as well as compositions comprising such compounds, salts, hydrates and prodrugs, are useful for treating and/or preventing fungal infections and associated diseases and conditions.
    Type: Grant
    Filed: August 7, 2009
    Date of Patent: May 29, 2012
    Assignees: Merck Sharp & Dohme Corp., Seynexis, Inc.
    Inventors: Mark L. Greenlee, Robert Wilkening, James Apgar, Donald Sperbeck, Kenneth J. Wildonger, Dongfang Meng, Dann L. Parker, Jr., Gregory J. Pacofsky, Brian H. Heasley, Ahmed Mamai, Kingsley Nelson
  • Publication number: 20120046269
    Abstract: The invention provides novel substituted amino azaheterocyclic carboxamide compounds according to Formula (I), their manufacture and use for the treatment of hyperproliferative diseases, such as cancer.
    Type: Application
    Filed: February 4, 2010
    Publication date: February 23, 2012
    Applicant: Merck Patent GmbH
    Inventors: Amanda E. Sutton, Ruoxi Lan, Thomas E. Richardson, David Perrey, Harold George Vandeveer, Bayard R. Huck, Srinivasa R. Karra, Xiaoling Chen, Lesley Liu-Bujalski, Andreas Goutopoulos, Frank Steiber, Brian L. Hodous, Hui Qiu, Reinaldo C. Jones, Brian H. Heasley
  • Patent number: 7820703
    Abstract: The present invention is directed to compositions comprising lysophosphatidic acid analogs and methods of using such analogs as agonist or antagonists of LPA receptor activity. In addition the invention is directed to LPA receptor agonists that vary in the degree of selectivity at individual LPA receptors (i.e. LPA1, LPA2 and LPA3). More particularly the present invention is directed to LPA analogs wherein the glycerol is replaced with ethanolamine and a variety of substitutions have been linked at the second carbon atom.
    Type: Grant
    Filed: May 6, 2005
    Date of Patent: October 26, 2010
    Assignee: University of Virginia Patent Foundation
    Inventors: Kevin R. Lynch, Timothy L. Macdonald, Brian H. Heasley
  • Publication number: 20100113439
    Abstract: Novel derivatives of enfumafungin are disclosed herein, along with their pharmaceutically acceptable salts, hydrates and prodrugs. Also disclosed are compositions comprising such compounds, methods of preparing such compounds and methods of using such compounds as antifungal agents and/or inhibitors of (1,3)-?-D-glucan synthase. The disclosed compounds, their pharmaceutically acceptable salts, hydrates and prodrugs, as well as compositions comprising such compounds, salts, hydrates and prodrugs, are useful for treating and/or preventing fungal infections and associated diseases and conditions.
    Type: Application
    Filed: August 7, 2009
    Publication date: May 6, 2010
    Applicants: Merck & Co., Inc., Scynexis, Inc.
    Inventors: Mark L. Greenlee, Robert Wilkening, James Apgar, Donald Sperbeck, Kenneth J. Wildonger, Dongfang Meng, Dann L. Parker, JR., Gregory J. Pacofsky, Brian H. Heasley, Ahmed Mamai, Kingsley Nelson
  • Publication number: 20100093790
    Abstract: Isoquinoline compounds with G are provided that influence, inhibit or reduce the action of a G-protein receptor kinase. Pharmaceutical compositions including therapeutically effective amounts of the isoquinoline compounds and pharmaceutically acceptable carriers are also provided. Various methods using the compounds and/or compositions to affect disease states or conditions such as cancer, osteoporosis and glaucoma are also provided.
    Type: Application
    Filed: December 16, 2009
    Publication date: April 15, 2010
    Applicant: AERIE PHARMACEUTICALS, INC.
    Inventors: Mitchell A. deLong, Marcos L. Sznaidman, Robert H. Oakley, Allen E. Eckhardt, Christine Hudson, Jeffrey D. Yingling, Michael Peel, Thomas E. Richardson, Clare Louise Murray, Byappanahally N. Narasinga Rao, Brian H. Heasley, Paresma R. Patel
  • Publication number: 20090069371
    Abstract: Isoquinoline compounds with G are provided that influence, inhibit or reduce the action of a G-protein receptor kinase. Pharmaceutical compositions including therapeutically effective amounts of the isoquinoline compounds and pharmaceutically acceptable carriers are also provided. Various methods using the compounds and/or compositions to affect disease states or conditions such as cancer, osteoporosis and glaucoma are also provided.
    Type: Application
    Filed: November 20, 2008
    Publication date: March 12, 2009
    Applicant: Aerie Pharmaceuticals, Inc.
    Inventors: Mitchell A. deLong, Marcos L. Sznaidman, Robert H. Oakley, Allen E. Eckhardt, Christine Hudson, Jeffrey D. Yingling, Michael Peel, Thomas E. Richardson, Clare Louise Murray, Byappanahally N. Narasinga Rao, Brian H. Heasley, Paresma R. Patel